Literature DB >> 17085265

Topiramate resolves headache from pseudotumor cerebri.

Josef Finsterer, Daniela Földy, Elisabeth Fertl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17085265     DOI： 10.1016/j.jpainsymman.2006.07.009

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


× No keyword cloud information.
  6 in total

1.  Misdiagnosed Bipolar Disorder Reveals Itself to be Posttraumatic Stress Disorder with Comorbid Pseudotumor Cerebri: A Case Report.

Authors:  Stephen Salzbrenner; Eileen Conaway
Journal:  Psychiatry (Edgmont)       Date:  2009-08

2.  High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure.

Authors:  Morgan B Smith; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Meir Wetzler; Craig W Freyer
Journal:  Leuk Res Rep       Date:  2014-07-30

Review 3.  Idiopathic intracranial hypertension: ongoing clinical challenges and future prospects.

Authors:  Parunyou Julayanont; Amputch Karukote; Doungporn Ruthirago; Deepa Panikkath; Ragesh Panikkath
Journal:  J Pain Res       Date:  2016-02-19       Impact factor: 3.133

Review 4.  Preclinical update on regulation of intracranial pressure in relation to idiopathic intracranial hypertension.

Authors:  Sajedeh Eftekhari; Connar Stanley James Westgate; Maria Schmidt Uldall; Rigmor Hoejland Jensen
Journal:  Fluids Barriers CNS       Date:  2019-11-26

5.  Emerging themes in idiopathic intracranial hypertension.

Authors:  Olivia Grech; Susan P Mollan; Benjamin R Wakerley; Zerin Alimajstorovic; Gareth G Lavery; Alexandra J Sinclair
Journal:  J Neurol       Date:  2020-07-22       Impact factor: 4.849

6.  Topiramate is more effective than acetazolamide at lowering intracranial pressure.

Authors:  William J Scotton; Hannah F Botfield; Connar Sj Westgate; James L Mitchell; Andreas Yiangou; Maria S Uldall; Rigmor H Jensen; Alex J Sinclair
Journal:  Cephalalgia       Date:  2018-06-13       Impact factor: 6.292
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.